Clarivate, a leader in global scientific and industry intelligence, has announced a new partnership to bring its regulatory insights into artificial intelligence workflows. By integrating its proprietary data with Claude, an advanced AI reasoning system, Clarivate aims to support life sciences organizations in making faster, more accurate regulatory decisions. This move is part of Clarivate’s broader strategy to embed its trusted industry knowledge into AI tools used across the healthcare and biotech sectors.

Enhancing AI with Trusted Regulatory Insights

The collaboration connects Clarivate’s Cortellis Regulatory Intelligence (CRI) data directly into Claude through an open protocol called the Model Context Protocol (MCP). This integration allows users to access authoritative regulatory information seamlessly within their existing AI workflows. The result is AI-powered answers that are both accurate and well-referenced, helping teams navigate complex regulatory landscapes more confidently.

For teams in regulatory affairs, pharmacovigilance, and other life sciences fields, this means they can now get direct, reliable insights from Clarivate’s validated sources during their decision-making processes. The MCP link embeds regulatory content into the AI environment, enabling users to build intelligent agents that combine CRI data with their own internal information and external sources. This helps monitor changes, assess risks, and support compliance activities more efficiently.

Expanding the Reach of Clarivate’s Industry Knowledge

This integration extends Clarivate’s regulatory intelligence into the AI ecosystems already popular among life sciences professionals. It builds on recent innovations, such as the launch of the CRI AI Assistant, and aims to automate routine tasks and generate anticipatory insights. By embedding trusted content directly into AI platforms like Claude, Clarivate is helping organizations accelerate their workflows and improve the quality of their regulatory decisions.

Henry Levy, President of Life Sciences & Healthcare at Clarivate, explained that this step advances their goal of embedding trusted intelligence into decision-making tools. He emphasized that integrating CRI into Claude broadens access to authoritative content, enabling life sciences companies to develop safer, more effective therapies faster. This collaboration supports the industry’s push toward smarter automation and more informed regulatory strategies.

Overall, this partnership marks a significant step forward in combining industry-validated data with cutting-edge AI technology. It empowers organizations to harness the full potential of their regulatory intelligence within familiar AI environments, ultimately enhancing their ability to bring new therapies to market and improve patient outcomes.

Inspired by

• https://ai-techpark.com/clarivate-expands-regulatory-intelligence-access-within-claude/